Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Moderna, Inc. — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 13.4× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Moderna, Inc. for 59 Days on average.
| JNK | MRNA | |
|---|---|---|
Market Cap | $5.86B | $78.65B |
Volume | 7,780,002 | 37,373,437 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $225.00 |
52-Week Low | $92.30 | $22.36 |
Typical Hold Time | 61 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.73, down 0.03% with a bearish technical outlook from moving averages. The ETF shows neutral oscillator signals but faces headwinds from rising bond yields and geopolitical tensions affecting high-yield debt markets. Recent institutional buying by Envestnet Asset Management indicates some professional interest despite market volatility.
The high-yield bond ETF faces pressure from rising interest rates and inflation concerns, though consistent dividend payments provide income support. Key risks include further Fed tightening and economic slowdown impacting junk bond defaults. Technical support at $92 could provide near-term stability if market sentiment improves.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
